利润表（科华生物）
| 上市前/上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 |
| 报表类型 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 |
| 一、营业总收入(元) | 1,350,223,553.61 | 908,526,752.98 | 443,303,887.87 | 2,428,075,213.95 | 1,904,222,528.93 | 1,396,475,774.51 | 833,147,693.69 |
| 营业收入(元) | 1,350,223,553.61 | 908,526,752.98 | 443,303,887.87 | 2,428,075,213.95 | 1,904,222,528.93 | 1,396,475,774.51 | 833,147,693.69 |
| 二、营业总成本(元) | 1,476,366,060.65 | 973,445,721.39 | 482,388,247.21 | 2,535,414,687.83 | 1,880,857,832.49 | 1,329,458,524.99 | 736,271,219.10 |
| 营业成本(元) | 809,534,413.84 | 541,247,222.45 | 256,898,023.74 | 1,399,855,969.40 | 1,058,730,070.33 | 762,787,408.91 | 442,543,620.30 |
| 研发费用(元) | 147,599,126.10 | 93,537,807.17 | 47,231,870.73 | 241,357,853.04 | 186,166,801.41 | 124,846,858.70 | 65,812,039.46 |
| 营业税金及附加(元) | 8,816,821.81 | 6,650,045.93 | 2,987,181.26 | 14,549,071.01 | 10,098,534.46 | 7,196,947.44 | 3,836,571.34 |
| 销售费用(元) | 264,541,013.78 | 172,891,851.32 | 95,185,872.85 | 458,472,466.77 | 349,871,548.34 | 254,487,788.54 | 128,490,377.04 |
| 管理费用(元) | 226,338,098.92 | 146,619,709.08 | 74,003,839.26 | 408,497,161.56 | 268,115,666.36 | 178,483,304.26 | 81,310,165.54 |
| 财务费用(元) | 19,536,586.20 | 12,499,085.44 | 6,081,459.37 | 12,682,166.05 | 7,875,211.59 | 1,656,217.14 | 14,278,445.42 |
| 其中：利息费用(元) | 35,394,425.50 | 24,015,369.67 | 11,831,392.49 | 43,742,300.34 | 32,371,285.68 | 21,188,752.17 | 10,245,731.73 |
| 其中：利息收入(元) | 18,038,066.80 | 12,450,776.85 | 4,664,811.88 | 30,980,785.71 | 22,925,767.73 | 19,130,203.42 | 7,954,256.41 |
| 三、其他经营收益 | |||||||
| 加：公允价值变动收益(元) | 953,315.21 | 590,817.03 | 2,751,486.18 | 1,471,746.93 | - | - | - |
| 加：投资收益(元) | 8,587,932.79 | 7,584,766.34 | 2,366,655.72 | 22,936,968.85 | 19,416,291.02 | 14,010,705.59 | 7,014,732.49 |
| 资产处置收益(元) | 2,185,685.63 | 1,723,405.40 | 566,673.46 | 5,018,213.91 | 1,559,467.57 | 546,963.35 | -507,086.16 |
| 资产减值损失(元) | -436,243.91 | -1,111,195.63 | 938,462.70 | -171,167,059.71 | -20,630,813.71 | -16,498,208.98 | 813,568.20 |
| 信用减值损失(元) | -15,668,028.52 | -6,054,641.88 | -1,061,254.57 | -17,355,243.94 | -1,608,073.93 | 582,551.66 | 2,340,720.57 |
| 其他收益(元) | 22,980,032.21 | 19,793,553.32 | 9,435,818.17 | 87,107,494.76 | 57,096,908.25 | 40,534,416.42 | 10,547,704.41 |
| 四、营业利润(元) | -107,539,813.63 | -42,392,263.83 | -24,086,517.68 | -179,327,353.08 | 79,198,475.64 | 106,193,677.56 | 117,086,114.10 |
| 加：营业外收入(元) | 391,904.40 | 228,520.24 | 91,438.47 | 1,554,498.70 | 409,105.18 | 240,713.90 | 287,638.46 |
| 减：营业外支出(元) | 3,218,684.48 | 1,656,669.99 | 461,463.78 | 7,835,980.72 | 4,341,331.52 | 2,032,138.72 | 1,028,112.58 |
| 五、利润总额(元) | -110,366,593.71 | -43,820,413.58 | -24,456,542.99 | -185,608,835.10 | 75,266,249.30 | 104,402,252.74 | 116,345,639.98 |
| 减：所得税费用(元) | -3,438,049.26 | -6,316,546.84 | -2,773,956.20 | -8,623,725.60 | 26,696,679.40 | 26,598,317.20 | 19,171,340.63 |
| 六、净利润(元) | -106,928,544.45 | -37,503,866.74 | -21,682,586.79 | -176,985,109.50 | 48,569,569.90 | 77,803,935.54 | 97,174,299.35 |
| (一)按经营持续性分类 | |||||||
| 持续经营净利润(元) | -106,928,544.45 | -37,503,866.74 | -21,682,586.79 | -176,985,109.50 | 48,569,569.90 | 77,803,935.54 | 97,174,299.35 |
| (二)按所有权归属分类 | |||||||
| 归属于母公司股东的净利润(元) | -122,140,657.33 | -52,464,103.69 | -28,821,454.12 | -234,014,886.40 | -19,954,130.67 | 21,128,073.92 | 54,761,876.98 |
| 少数股东损益(元) | 15,212,112.88 | 14,960,236.95 | 7,138,867.33 | 57,029,776.90 | 68,523,700.57 | 56,675,861.62 | 42,412,422.37 |
| 扣除非经常性损益后的净利润(元) | -144,875,725.42 | -74,540,507.67 | -39,116,563.64 | -280,013,001.34 | -37,844,049.48 | 6,885,105.47 | 48,141,247.97 |
| 七、每股收益 | |||||||
| 一、基本每股收益(元) | -0.24 | -0.10 | -0.06 | -0.46 | -0.04 | 0.04 | 0.11 |
| 二、稀释每股收益(元) | -0.24 | -0.10 | -0.06 | -0.46 | -0.04 | 0.04 | 0.11 |
| 八、其他综合收益(元) | -1,734,692.20 | -9,747,466.32 | -9,052,139.94 | 5,095,342.54 | 15,889,170.35 | 23,703,323.59 | -2,293,123.09 |
| 归属于母公司股东的其他综合收益(元) | -1,459,628.85 | -7,858,493.21 | -7,326,715.41 | 677,590.41 | 14,118,920.97 | 19,010,904.23 | -1,933,888.65 |
| 归属于少数股东的其他综合收益(元) | -275,063.35 | -1,888,973.11 | -1,725,424.53 | 4,417,752.13 | 1,770,249.38 | 4,692,419.36 | -359,234.44 |
| 九、综合收益总额(元) | -108,663,236.65 | -47,251,333.06 | -30,734,726.73 | -171,889,766.96 | 64,458,740.25 | 101,507,259.13 | 94,881,176.26 |
| 归属于母公司所有者的综合收益总额(元) | -123,600,286.18 | -60,322,596.90 | -36,148,169.53 | -233,337,295.99 | -5,835,209.70 | 40,138,978.15 | 52,827,988.33 |
| 归属于少数股东的综合收益总额(元) | 14,937,049.53 | 13,071,263.84 | 5,413,442.80 | 61,447,529.03 | 70,293,949.95 | 61,368,280.98 | 42,053,187.93 |
| 公告日期 | 2024-10-22 | 2024-08-30 | 2024-04-29 | 2024-03-23 | 2023-10-28 | 2023-08-17 | 2023-04-22 |
| 审计意见(境内) | 标准无保留意见 | ||||||
| 原始财报文件下载 | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) |
| 上市前/上市后 |
| 报表类型 |
| 一、营业总收入(元) |
| 营业收入(元) |
| 二、营业总成本(元) |
| 营业成本(元) |
| 研发费用(元) |
| 营业税金及附加(元) |
| 销售费用(元) |
| 管理费用(元) |
| 财务费用(元) |
| 其中：利息费用(元) |
| 其中：利息收入(元) |
| 三、其他经营收益 |
| 加：公允价值变动收益(元) |
| 加：投资收益(元) |
| 资产处置收益(元) |
| 资产减值损失(元) |
| 信用减值损失(元) |
| 其他收益(元) |
| 四、营业利润(元) |
| 加：营业外收入(元) |
| 减：营业外支出(元) |
| 五、利润总额(元) |
| 减：所得税费用(元) |
| 六、净利润(元) |
| (一)按经营持续性分类 |
| 持续经营净利润(元) |
| (二)按所有权归属分类 |
| 归属于母公司股东的净利润(元) |
| 少数股东损益(元) |
| 扣除非经常性损益后的净利润(元) |
| 七、每股收益 |
| 一、基本每股收益(元) |
| 二、稀释每股收益(元) |
| 八、其他综合收益(元) |
| 归属于母公司股东的其他综合收益(元) |
| 归属于少数股东的其他综合收益(元) |
| 九、综合收益总额(元) |
| 归属于母公司所有者的综合收益总额(元) |
| 归属于少数股东的综合收益总额(元) |
| 公告日期 |
| 审计意见(境内) |
| 原始财报文件下载 |
Showing 1 to 44 of 44 entries